Clinical Cancer Research The Science of Cancer Health Disparities
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Knox, S. J.
Right arrow Articles by Levy, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Knox, S. J.
Right arrow Articles by Levy, R.

Clinical Cancer Research, Vol 2, Issue 3 457-470, Copyright © 1996 by American Association for Cancer Research

ARTICLES

Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma

SJ Knox, ML Goris, K Trisler, R Negrin, T Davis, TM Liles, A Grillo-Lopez, P Chinn, C Varns, SC Ning, S Fowler, N Deb, M Becker, C Marquez and R Levy
Departments of Radiation Oncology, Diagnostic Radiology, Division of Nuclear Medicine, Stanford University School of Medicine, Stanford, California, 94305, USA.

A Phase I/II dose escalation study of 90Y-murine anti-CD20 monoclonal antibody (mAb) in patients with recurrent B-cell lymphoma was performed. The primary objectives of the study were: (a) to determine the effect of the preinfusion of unlabeled anti-CD20 mAb on the biodistribution of 111In-anti-CD20 mAb; (b) to determine the maximal tolerated dose of 90Y-anti-CD20 mAb that does not require bone marrow transplantation; and (c) to evaluate the safety and antitumor effect of 90Y-anti-CD20 mAb in patients with recurrent B-cell lymphoma. Eighteen patients with relapsed low- or intermediate-grade non-Hodgkin's lymphoma were treated. Biodistribution studies with 111In-anti-CD20 mAb were performed prior to therapy. Groups of three or four patients were treated at dose levels of approximately 13.5, 20, 30, 40, and 50 mCi 90Y-anti-CD20 mAb. Three patients were retreated at the 40-mCi dose level. The use of unlabeled antibody affected the biodistribution favorably. Nonhematological toxicity was minimal. The only significant toxicity was myelosuppression. The overall response rate following a single dose of 90Y-anti-CD20 mAb therapy was 72%, with six complete responses and seven partial responses and freedom from progression of 3-29+ months following treatment. Radioimmunotherapy with </=50 mCi 90Y-anti-CD20 mAb resulted in minimal nonhematological toxicity and durable clinical responses in patients with recurrent B-cell lymphoma. Doses of </=40 mCi 90Y-anti-CD20 mAb were not myeloablative.


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
A. Ivanov, S. Krysov, M. S. Cragg, and T. Illidge
Radiation Therapy with Tositumomab (B1) Anti-CD20 Monoclonal Antibody Initiates Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase-Dependent Cell Death that Overcomes Resistance to Apoptosis
Clin. Cancer Res., August 1, 2008; 14(15): 4925 - 4934.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. K. Gopal, O. W. Press, S. M. Wilbur, D. G. Maloney, and J. M. Pagel
Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab
Blood, August 1, 2008; 112(3): 830 - 835.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Zhang, Z. Yao, H. Patel, K. Garmestani, Z. Zhang, V. S. Talanov, P. S. Plascjak, C. K. Goldman, J. E. Janik, M. W. Brechbiel, et al.
Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1
PNAS, May 15, 2007; 104(20): 8444 - 8448.
[Abstract] [Full Text] [PDF]

Home page
 CLIN APPL THROMB HEMOSTHome page
S. Nomura, K. Ishii, Y. Kamitsuji, N. Uoshima, E. Ishikawa, H. Kitayama, and K. Hayashi
Elevation of Activated Platelet-Dependent Chemokines in Patients With Anti-CD20 Monoclonal Antibody (Rituximab)-Treated Non-Hodgkin's Lymphoma
Clinical and Applied Thrombosis/Hemostasis, April 1, 2007; 13(2): 206 - 212.
[Abstract] [PDF]

Home page
 Cancer Res.Home page
M. Zhang, Z. Yao, Z. Zhang, K. Garmestani, V. S. Talanov, P. S. Plascjak, S. Yu, H.-S. Kim, C. K. Goldman, C. H. Paik, et al.
The Anti-CD25 Monoclonal Antibody 7G7/B6, Armed with the {alpha}-Emitter 211At, Provides Effective Radioimmunotherapy for a Murine Model of Leukemia
Cancer Res., August 15, 2006; 66(16): 8227 - 8232.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Z. Zhang, M. Zhang, K. Garmestani, V. S. Talanov, P. S. Plascjak, B. Beck, C. Goldman, M. W. Brechbiel, and T. A. Waldmann
Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25
Blood, August 1, 2006; 108(3): 1007 - 1012.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. M. Pagel, F. R. Appelbaum, J. F. Eary, J. Rajendran, D. R. Fisher, T. Gooley, K. Ruffner, E. Nemecek, E. Sickle, L. Durack, et al.
131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission
Blood, March 1, 2006; 107(5): 2184 - 2191.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. M. Richman, S. J. DeNardo, R. T. O'Donnell, A. Yuan, S. Shen, D. S. Goldstein, J. M. Tuscano, T. Wun, H. K. Chew, P. N. Lara, et al.
High-Dose Radioimmunotherapy Combined with Fixed, Low-Dose Paclitaxel in Metastatic Prostate and Breast Cancer by Using a MUC-1 Monoclonal Antibody, m170, Linked to Indium-111/Yttrium-90 via a Cathepsin Cleavable Linker with Cyclosporine to Prevent Human Anti-mouse Antibody
Clin. Cancer Res., August 15, 2005; 11(16): 5920 - 5927.
[Abstract] [Full Text] [PDF]

Home page
 Clin Med ResHome page
A. V. Rao, G. Akabani, and D. A. Rizzieri
Radioimmunotherapy for Non-Hodgkin's Lymphoma
Clin. Med. Res., August 1, 2005; 3(3): 157 - 165.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. H. Bander, M. I. Milowsky, D. M. Nanus, L. Kostakoglu, S. Vallabhajosula, and S. J. Goldsmith
Phase I Trial of 177Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer
J. Clin. Oncol., July 20, 2005; 23(21): 4591 - 4601.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
S. Shen, S. J. DeNardo, C. M. Richman, A. Yuan, C. H. Siantar, R. T. O'Donnell, L. A. Kroger, and G. L. DeNardo
Planning Time for Peripheral Blood Stem Cell Infusion After High-Dose Targeted Radionuclide Therapy Using Dosimetry
J. Nucl. Med., June 1, 2005; 46(6): 1034 - 1041.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
S. Vallabhajosula, I. Kuji, K. A. Hamacher, S. Konishi, L. Kostakoglu, P. A. Kothari, M. I. Milowski, D. M. Nanus, N. H. Bander, and S. J. Goldsmith
Pharmacokinetics and Biodistribution of 111In- and 177Lu-Labeled J591 Antibody Specific for Prostate-Specific Membrane Antigen: Prediction of 90Y-J591 Radiation Dosimetry Based on 111In or 177Lu?
J. Nucl. Med., April 1, 2005; 46(4): 634 - 641.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. L. Palomba, W. K. Roberts, T. Dao, G. Manukian, J. A. Guevara-Patino, J. D. Wolchok, D. A. Scheinberg, and A. N. Houghton
CD8+ T-Cell-Dependent Immunity Following Xenogeneic DNA Immunization against CD20 in a Tumor Challenge Model of B-Cell Lymphoma
Clin. Cancer Res., January 1, 2005; 11(1): 370 - 379.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. E. Milenic, K. Garmestani, E. D. Brady, P. S. Albert, D. Ma, A. Abdulla, and M. W. Brechbiel
Targeting of HER2 Antigen for the Treatment of Disseminated Peritoneal Disease
Clin. Cancer Res., December 1, 2004; 10(23): 7834 - 7841.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. I. Milowsky, D. M. Nanus, L. Kostakoglu, S. Vallabhajosula, S. J. Goldsmith, and N. H. Bander
Phase I Trial of Yttrium-90--Labeled Anti--Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Androgen-Independent Prostate Cancer
J. Clin. Oncol., July 1, 2004; 22(13): 2522 - 2531.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. I. Gordon, A. Molina, T. Witzig, C. Emmanouilides, A. Raubtischek, M. Darif, R. J. Schilder, G. Wiseman, and C. A. White
Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study
Blood, June 15, 2004; 103(12): 4429 - 4431.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y. Du, J. Honeychurch, M. S. Cragg, M. Bayne, M. J. Glennie, P. W. M. Johnson, and T. M. Illidge
Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy
Blood, February 15, 2004; 103(4): 1485 - 1494.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
R. M. Sharkey, A. Brenner, J. Burton, G. Hajjar, S. P. Toder, A. Alavi, A. Matthies, D. E. Tsai, S. J. Schuster, E. A. Stadtmauer, et al.
Radioimmunotherapy of Non-Hodgkin's Lymphoma with 90Y-DOTA Humanized Anti-CD22 IgG (90Y-Epratuzumab): Do Tumor Targeting and Dosimetry Predict Therapeutic Response?
J. Nucl. Med., December 1, 2003; 44(12): 2000 - 2018.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Y. C. Wong, S. Shibata, L. E. Williams, C. S. Kwok, A. Liu, D. Z. Chu, D. M. Yamauchi, S. Wilczynski, D. N. Ikle, A. M. Wu, et al.
A Phase I Trial of 90Y-Anti-Carcinoembryonic Antigen Chimeric T84.66 Radioimmunotherapy with 5-Fluorouracil in Patients with Metastatic Colorectal Cancer
Clin. Cancer Res., December 1, 2003; 9(16): 5842 - 5852.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
O. W. Press, J. M. Unger, R. M. Braziel, D. G. Maloney, T. P. Miller, M. LeBlanc, E. R. Gaynor, S. E. Rivkin, and R. I. Fisher
A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911
Blood, September 1, 2003; 102(5): 1606 - 1612.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. P. Leonard, M. Coleman, J. C. Ketas, A. Chadburn, S. Ely, R. R. Furman, W. A. Wegener, H. J. Hansen, H. Ziccardi, M. Eschenberg, et al.
Phase I/II Trial of Epratuzumab (Humanized Anti-CD22 Antibody) in Indolent Non-Hodgkin's Lymphoma
J. Clin. Oncol., August 15, 2003; 21(16): 3051 - 3059.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
C. L. Hartmann Siantar, G. L. DeNardo, and S. J. DeNardo
Impact of Nodal Regression on Radiation Dose for Lymphoma Patients After Radioimmunotherapy
J. Nucl. Med., August 1, 2003; 44(8): 1322 - 1329.
[Abstract] [Full Text] [PDF]

Home page
 J. Nucl. Med. Technol.Home page
D. M. Fink-Bennett and K. Thomas
90Y-Ibritumomab Tiuxetan in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
J. Nucl. Med. Technol., June 1, 2003; 31(2): 61 - 68.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. E. Witzig, C. A. White, L. I. Gordon, G. A. Wiseman, C. Emmanouilides, J. L. Murray, J. Lister, and P. S. Multani
Safety of Yttrium-90 Ibritumomab Tiuxetan Radioimmunotherapy for Relapsed Low-Grade, Follicular, or Transformed Non-Hodgkin's Lymphoma
J. Clin. Oncol., April 1, 2003; 21(7): 1263 - 1270.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. M. Pagel, N. Hedin, K. Subbiah, D. Meyer, R. Mallet, D. Axworthy, L. J. Theodore, D. S. Wilbur, D. C. Matthews, and O. W. Press
Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas
Blood, March 15, 2003; 101(6): 2340 - 2348.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
D. J. Buchsbaum and A. F. LoBuglio
Targeting of 125I-Labeled B Lymphocyte Stimulator
J. Nucl. Med., March 1, 2003; 44(3): 434 - 436.
[Full Text] [PDF]

Home page
 JNMHome page
K. Subbiah, D. K. Hamlin, J. M. Pagel, D. S. Wilbur, D. L. Meyer, D. B. Axworthy, R. W. Mallett, L. J. Theodore, P. S. Stayton, and O. W. Press
Comparison of Immunoscintigraphy, Efficacy, and Toxicity of Conventional and Pretargeted Radioimmunotherapy in CD20-Expressing Human Lymphoma Xenografts
J. Nucl. Med., March 1, 2003; 44(3): 437 - 445.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Zhang, Z. Zhang, K. Garmestani, J. Schultz, D. B. Axworthy, C. K. Goldman, M. W. Brechbiel, J. A. Carrasquillo, and T. A. Waldmann
Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts
PNAS, February 18, 2003; 100(4): 1891 - 1895.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B. D. Cheson
Radioimmunotherapy of non-Hodgkin lymphomas
Blood, January 15, 2003; 101(2): 391 - 398.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. E. Juweid
Radioimmunotherapy of B-Cell Non-Hodgkin's Lymphoma: From Clinical Trials to Clinical Practice
J. Nucl. Med., November 1, 2002; 43(11): 1507 - 1529.
[Abstract] [Full Text] [PDF]

Home page
 Arch OphthalmolHome page
B. Esmaeli, J. L. Murray, M. A. Ahmadi, A. Naderi, S. Singh, J. Romaguera, C. A. White, and P. McLaughlin
Immunotherapy for Low-Grade Non-Hodgkin Secondary Lymphoma of the Orbit
Arch Ophthalmol, September 1, 2002; 120(9): 1225 - 1227.
[Full Text] [PDF]

Home page
 JCOHome page
R. O. Dillman
Radiolabeled Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoma
J. Clin. Oncol., August 15, 2002; 20(16): 3545 - 3557.
[Full Text] [PDF]

Home page
 JCOHome page
T. E. Witzig, I. W. Flinn, L. I. Gordon, C. Emmanouilides, M. S. Czuczman, M. N. Saleh, L. Cripe, G. Wiseman, T. Olejnik, P. S. Multani, et al.
Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma
J. Clin. Oncol., August 1, 2002; 20(15): 3262 - 3269.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
T. Igarashi, Y. Kobayashi, M. Ogura, T. Kinoshita, T. Ohtsu, Y. Sasaki, Y. Morishima, T. Murate, M. Kasai, N. Uike, et al.
Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study
Ann. Onc., June 1, 2002; 13(6): 928 - 943.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. E. Witzig, L. I. Gordon, F. Cabanillas, M. S. Czuczman, C. Emmanouilides, R. Joyce, B. L. Pohlman, N. L. Bartlett, G. A. Wiseman, N. Padre, et al.
Randomized Controlled Trial of Yttrium-90-Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma
J. Clin. Oncol., May 15, 2002; 20(10): 2453 - 2463.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
H. N. Wagner Jr., G. A. Wiseman, C. S. Marcus, H. A. Nabi, C. E. Nagle, D. M. Fink-Bennett, D. M. Lamonica, and P. S. Conti
Administration Guidelines for Radioimmunotherapy of Non-Hodgkin's Lymphoma with 90Y-Labeled Anti-CD20 Monoclonal Antibody
J. Nucl. Med., February 1, 2002; 43(2): 267 - 272.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. E. Perico, M. Chinol, A. Nacca, E. Luison, G. Paganelli, and S. Canevari
The Humoral Immune Response to Macrocyclic Chelating Agent DOTA Depends on the Carrier Molecule
J. Nucl. Med., November 1, 2001; 42(11): 1697 - 1703.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
O. W. Press, M. Corcoran, K. Subbiah, D. K. Hamlin, D. S. Wilbur, T. Johnson, L. Theodore, E. Yau, R. Mallett, D. L. Meyer, et al.
A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts
Blood, October 15, 2001; 98(8): 2535 - 2543.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
A. Lovqvist, J. L. Humm, A. Sheikh, R. D. Finn, J. Koziorowski, S. Ruan, K. S. Pentlow, A. Jungbluth, S. Welt, F. T. Lee, et al.
PET Imaging of 86Y-Labeled Anti-Lewis Y Monoclonal Antibodies in a Nude Mouse Model: Comparison Between 86Y and 111In Radiolabels
J. Nucl. Med., August 1, 2001; 42(8): 1281 - 1287.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
O. W. Press, J. P. Leonard, B. Coiffier, R. Levy, and J. Timmerman
Immunotherapy of Non-Hodgkin's Lymphomas
Hematology, January 1, 2001; 2001(1): 221 - 240.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Colombat, G. Salles, N. Brousse, P. Eftekhari, P. Soubeyran, V. Delwail, E. Deconinck, C. Haioun, C. Foussard, C. Sebban, et al.
Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation
Blood, January 1, 2001; 97(1): 101 - 106.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Y. C. Wong, D. Z. Chu, D. M. Yamauchi, L. E. Williams, A. Liu, S. Wilczynski, A. M. Wu, J. E. Shively, J. H. Doroshow, and A. A. Raubitschek
A Phase I Radioimmunotherapy Trial Evaluating 90Yttrium-labeled Anti-Carcinoembryonic Antigen (CEA) Chimeric T84.66 in Patients with Metastatic CEA-producing Malignancies
Clin. Cancer Res., October 1, 2000; 6(10): 3855 - 3863.
[Abstract] [Full Text]

Home page
 BloodHome page
M. S. Kaminski, J. Estes, K. R. Zasadny, I. R. Francis, C. W. Ross, M. Tuck, D. Regan, S. Fisher, J. Gutierrez, S. Kroll, et al.
Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience
Blood, August 15, 2000; 96(4): 1259 - 1266.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. H. Pai-Scherf, J. A. Carrasquillo, C. Paik, O. Gansow, M. Whatley, D. Pearson, K. Webber, M. Hamilton, C. Allegra, M. Brechbiel, et al.
Imaging and Phase I Study of 111In- and 90Y-labeled Anti-LewisY Monoclonal Antibody B3
Clin. Cancer Res., May 1, 2000; 6(5): 1720 - 1730.
[Abstract] [Full Text]

Home page
 Proc. Natl. Acad. Sci. USAHome page
D. B. Axworthy, J. M. Reno, M. D. Hylarides, R. W. Mallett, L. J. Theodore, L. M. Gustavson, F.-M. Su, L. J. Hobson, P. L. Beaumier, and A. R. Fritzberg
Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity
PNAS, February 15, 2000; 97(4): 1802 - 1807.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. E. Witzig, C. A. White, G. A. Wiseman, L. I. Gordon, C. Emmanouilides, A. Raubitschek, N. Janakiraman, J. Gutheil, R. J. Schilder, S. Spies, et al.
Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20+ B-Cell Non-Hodgkin's Lymphoma
J. Clin. Oncol., December 1, 1999; 17(12): 3793 - 3803.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
O. C. Boerman, M. H. G. C. Kranenborg, E. Oosterwijk, G. L. Griffiths, W. J. McBride, W. J. G. Oyen, M. de Weijert, J. Oosterwijk-Wakka, H. J. Hansen, and F. H. M. Corstens
Pretargeting of Renal Cell Carcinoma: Improved Tumor Targeting with a Bivalent Chelate
Cancer Res., September 1, 1999; 59(17): 4400 - 4405.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. C. Matthews, F. R. Appelbaum, J. F. Eary, D. R. Fisher, L. D. Durack, T. E. Hui, P. J. Martin, D. Mitchell, O. W. Press, R. Storb, et al.
Phase I Study of 131I-Anti-CD45 Antibody Plus Cyclophosphamide and Total Body Irradiation for Advanced Acute Leukemia and Myelodysplastic Syndrome
Blood, August 15, 1999; 94(4): 1237 - 1247.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. M. Illidge, M. S. Cragg, H. M. McBride, R. R. French, and M. J. Glennie
The Importance of Antibody-Specificity in Determining Successful Radioimmunotherapy of B-Cell Lymphoma
Blood, July 1, 1999; 94(1): 233 - 243.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. Shan, O. W. Press, T. T. Tsu, M. S. Hayden, and J. A. Ledbetter
Characterization of scFv-Ig Constructs Generated from the Anti-CD20 mAb 1F5 Using Linker Peptides of Varying Lengths
J. Immunol., June 1, 1999; 162(11): 6589 - 6595.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. Shan, J. A. Ledbetter, and O. W. Press
Apoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal Antibodies
Blood, March 1, 1998; 91(5): 1644 - 1652.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. G. Maloney, A. J. Grillo-Lopez, C. A. White, D. Bodkin, R. J. Schilder, J. A. Neidhart, N. Janakiraman, K. A. Foon, T.-M. Liles, B. K. Dallaire, et al.
IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma
Blood, September 15, 1997; 90(6): 2188 - 2195.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1996 by the American Association for Cancer Research.